FOLFOX6 + FOLFOXIRI

FOLFOX6 + FOLFOXIRI refers to the sequential or combined use of two multi-agent chemotherapy regimens, each used primarily for the treatment of advanced or metastatic colorectal cancer. Both regimens are based on combinations of cytotoxic agents that target rapidly dividing cells. - **FOLFOX6** consists of oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU). Oxaliplatin is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. Leucovorin enhances the binding of 5-FU to its target enzyme, increasing its efficacy. 5-FU is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in cancer cells[1][2][3][4][5][6][8][9]. - **FOLFOXIRI** combines oxaliplatin, irinotecan (a topoisomerase I inhibitor), leucovorin (folinic acid), and fluorouracil. Irinotecan adds a mechanism by inhibiting topoisomerase I, leading to DNA damage during replication[7][10]. Both regimens are administered intravenously in cycles every 14 days. They are standard-of-care options for metastatic colorectal cancer; their combination or sequence may be considered in aggressive disease settings.